LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

LLY

1,043.44

-0.5%↓

JNJ

244.93

-0.74%↓

ABBV

231.82

+1.2%↑

NVS

167.49

+0.26%↑

MRK

123.99

+0.36%↑

Search

Twist Bioscience Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

49.93 2.21

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

47.67

Max

50.09

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-3.4M

-31M

Pardavimai

4.7M

104M

Pelno marža

-29.419

Darbuotojai

979

EBITDA

-3.2M

-24M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+8.13% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

409M

3B

Ankstesnė atidarymo kaina

47.72

Ankstesnė uždarymo kaina

49.93

Naujienos nuotaikos

By Acuity

50%

50%

161 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Twist Bioscience Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-24 23:07; UTC

Uždarbis

Woolworths 1st Half Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026-02-24 23:01; UTC

Uždarbis

Fortescue 1st Half Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026-02-24 22:59; UTC

Uždarbis

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability -- Update

2026-02-24 22:42; UTC

Uždarbis

WiseTech to Cut 2,000 Jobs as It Asks AI to Boost Profitability

2026-02-24 22:24; UTC

Įsigijimai, susijungimai, perėmimai

Warner Bros. Discovery Board Says Paramount Skydance's New Proposal Could Top Netflix Agreement -- Update

2026-02-24 23:46; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Possible Position Adjustments -- Market Talk

2026-02-24 23:36; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Rebound -- Market Talk

2026-02-24 23:30; UTC

Rinkos pokalbiai

Fortescue's Copper Bet Is Long Term, While Iron Ore Remains Near-Term Driver -- Market Talk

2026-02-24 23:20; UTC

Rinkos pokalbiai

Fortescue Dividend Beat Overshadows Profit Miss -- Market Talk

2026-02-24 23:20; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-24 23:16; UTC

Uždarbis

Oversea-Chinese Banking Corp.'s CEO: "Looking Ahead, We Remain Cautious Yet Positive">O39.SG

2026-02-24 23:13; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Non-Interest Income S$5.46B Vs. S$4.72B >O39.SG

2026-02-24 23:12; UTC

Uždarbis

Oversea-Chinese Banking Corp.: FY25 Net Interest Income S$9.15B Vs. S$9.76B>O39.SG

2026-02-24 23:10; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 NPL Ratio 0.9%, Unchanged on Year>O39.SG

2026-02-24 23:10; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Net Interest Margin 1.91%, Down 29bps on Year>O39.SG

2026-02-24 23:08; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Net S$7.42B Vs. Net S$7.59B >O39.SG

2026-02-24 23:07; UTC

Uždarbis

Oversea-Chinese Banking Corp. FY25 Total Income S$14.61B Vs. S$14.47B>O39.SG

2026-02-24 22:52; UTC

Uždarbis

Woolworths 1H Profit Hit By Worker Pay Dispute, Still Boosts Dividend

2026-02-24 22:46; UTC

Uždarbis

Fortescue 1H Net Profit, Dividend Rise on Higher Shipments, Prices -- Update

2026-02-24 22:31; UTC

Įsigijimai, susijungimai, perėmimai

Warner Receives New Bid From Paramount -- 3rd Update

2026-02-24 22:29; UTC

Uždarbis

Woolworths: FY Ebit Growth for Australian Food Expected at Upper End of Mid-to-High Single Digit Range Provided in August

2026-02-24 22:28; UTC

Uždarbis

Woolworths: Australian Food Current Growth Rates Reflect Some Benefit from Cycling of Industrial Action Impacts

2026-02-24 22:27; UTC

Uždarbis

Woolworths: Australian Food Sales +7.2% Excluding Tobacco in 2H First Seven Weeks

2026-02-24 22:27; UTC

Uždarbis

Woolworths: Australian Food Sales +5.8% in 2H First Seven Weeks

2026-02-24 22:25; UTC

Uždarbis

Woolworths: Customers Continue to be Value-Focused, Shopping Multiple Retailers in Highly Competitive Environment

2026-02-24 22:24; UTC

Uždarbis

Woolworths: Trading in 3Q to Date Has Been Strong in Australian Food

2026-02-24 22:23; UTC

Uždarbis

Woolworths 1H Group Sales A$37.1 Bln, Up 3.4%

2026-02-24 22:22; UTC

Uždarbis

Woolworths Interim Dividend 45 Australian Cents/Share

2026-02-24 22:22; UTC

Uždarbis

Woolworths 1H Profit Before Significant Items A$859 Mln, Up 16.4%

2026-02-24 22:21; UTC

Uždarbis

Woolworths 1H Statutory Net Profit A$374 Mln, Down 49.4%

Akcijų palyginimas

Kainos pokytis

Twist Bioscience Corp Prognozė

Kainos tikslas

By TipRanks

8.13% į viršų

12 mėnesių prognozė

Vidutinis 52 USD  8.13%

Aukščiausias 58 USD

Žemiausias 50 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Twist Bioscience Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

6

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

31.56 / 38.6884Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

161 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat